Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Cash from Financing Activities: 2016-2024

Historic Cash from Financing Activities for Mereo BioPharma Group (MREO) over the last 9 years, with Dec 2024 value amounting to $46.1 million.

  • Mereo BioPharma Group's Cash from Financing Activities fell 100.29% to -$134,000 in Q2 2025 from the same period last year, while for Jun 2025 it was -$346,000, marking a year-over-year change of. This contributed to the annual value of $46.1 million for FY2024, which is 478.79% up from last year.
  • As of FY2024, Mereo BioPharma Group's Cash from Financing Activities stood at $46.1 million, which was up 478.79% from $8.0 million recorded in FY2023.
  • Mereo BioPharma Group's Cash from Financing Activities' 5-year high stood at $104.7 million during FY2021, with a 5-year trough of $200,000 in FY2022.
  • In the last 3 years, Mereo BioPharma Group's Cash from Financing Activities had a median value of $8.0 million in 2023 and averaged $18.1 million.
  • In the last 5 years, Mereo BioPharma Group's Cash from Financing Activities slumped by 99.81% in 2022 and then soared by 3,886.50% in 2023.
  • Over the past 5 years, Mereo BioPharma Group's Cash from Financing Activities (Yearly) stood at $44.6 million in 2020, then skyrocketed by 134.66% to $104.7 million in 2021, then crashed by 99.81% to $200,000 in 2022, then soared by 3,886.50% to $8.0 million in 2023, then surged by 478.79% to $46.1 million in 2024.